The aim of our study was to evaluate the metabolic and clinical effects of a contraceptive treatment with a new tri-phasic formulation of ethynyl-estradiol (35μg) and norethisterone (0.5-1mg) in fertile women.For thi...The aim of our study was to evaluate the metabolic and clinical effects of a contraceptive treatment with a new tri-phasic formulation of ethynyl-estradiol (35μg) and norethisterone (0.5-1mg) in fertile women.For this purpose 20 healthy fertile women (19-32years) volunteered to follow this trial.High-density lipoprotein cholesterol,low-density lipoprotion cholesterol,fibrinogen concentration and antithrombin Ⅲ were measured by enzymatic method and fibrinopeptides A,by RIA.The patients were treated for 6 cycles and they were studied before and after 1,3, and 6 cycles of treatment.In all patients both the length of the menstrual cycle,and bleeding,acne and seborrhea and side effects were evaluated.The contraceptive therapy with this new formulation resulted very effective,without significant metabolic changes and with very few side effects.展开更多
文摘The aim of our study was to evaluate the metabolic and clinical effects of a contraceptive treatment with a new tri-phasic formulation of ethynyl-estradiol (35μg) and norethisterone (0.5-1mg) in fertile women.For this purpose 20 healthy fertile women (19-32years) volunteered to follow this trial.High-density lipoprotein cholesterol,low-density lipoprotion cholesterol,fibrinogen concentration and antithrombin Ⅲ were measured by enzymatic method and fibrinopeptides A,by RIA.The patients were treated for 6 cycles and they were studied before and after 1,3, and 6 cycles of treatment.In all patients both the length of the menstrual cycle,and bleeding,acne and seborrhea and side effects were evaluated.The contraceptive therapy with this new formulation resulted very effective,without significant metabolic changes and with very few side effects.
